Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Arrowhead Pharmaceuticals, Inc. (ARWR) vs Caris Life Sciences,�Inc. (CAI)

Arrowhead Pharmaceuticals, Inc. and Caris Life Sciences,�Inc. are both Biotechnology companies. Arrowhead Pharmaceuticals, Inc. and Caris Life Sciences,�Inc. are of similar size ($9.3B and $9.1B). Arrowhead Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 85.1×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 96.4% against 16.1%. Caris Life Sciences,�Inc. has the higher net margin (8.15% vs −47.8%) and the higher return on invested capital (50.0% vs 0.00%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 13 and Arrowhead Pharmaceuticals, Inc. on 4.

Valuation

Metric ARWR CAI Biotechnology median
P/E n/m 85.08 7.88
P/S 14.12 9.14 11.47
P/B 20.28 15.29 2.52
Price to free cash flow n/m 72.98 21.16
EV/EBITDA n/m 48.03 0.74
EV/Sales 13.02 8.74 10.73
Earnings yield (3.41%) 1.18% (28.84%)
Free cash flow yield (0.79%) 1.37% (23.03%)

Profitability

Metric ARWR CAI Biotechnology median
Gross margin 100.00% 69.66% 65.16%
Operating margin (33.82%) 15.49% 0.00%
Net margin (47.79%) 8.15% 0.00%
Free cash flow margin (11.22%) 12.53% 0.00%
Return on equity (64.91%) 15.45% (57.72%)
Return on assets (18.32%) 7.39% (49.22%)
Return on invested capital 0.00% 49.95% 0.00%

Growth

Metric ARWR CAI Biotechnology median
Revenue growth (TTM) 16.13% 96.36% 5.64%
EPS growth (last fiscal year) 99.80% 59.45% —
Revenue growth, 5-year CAGR 56.63% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ARWR CAI Biotechnology median
Debt to equity 1.85 0.66 0.00
Current ratio 5.90 5.53 4.73
Net debt to EBITDA (5.70) (5.23) 0.96

Dividend

Metric ARWR CAI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ARWR CAI Biotechnology median
Market cap 9.33b 9.12b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack